FDA approves enhanced Philips LumiGuide endovascular navigation wire
September 17, 2024
Philips (NYSE: PHG)+
announced today that it introduced the FDA-approved, 160 cm version of its LumiGuide endovascular navigation wire.
Philips (NYSE: PHG)+
announced today that it introduced the FDA-approved, 160 cm version of its LumiGuide endovascular navigation wire.
Edwards Lifesciences (NYSE: EW)+
announced that it launched its Sapien 3 transcatheter pulmonary valve implant (TPVI) system with Alterra adaptive prestent in Europe.
Medtronic (NYSE: MDT)+
today announced the publication of its novel approach to studying adaptive deep brain stimulation (aDBS).
Commercial partner Ascensia is in discussions with insulin pump manufacturers to create an automated insulin delivery system.
Biotronik announced today that it received FDA approval for its Selectra 3D catheter and Solia S lead for use in left bundle branch area pacing (LBBAP).
The company says that Lightning Flash 2.0 will be the most advanced thrombectomy system on the European market to address venous and pulmonary thrombus.
Johnson & Johnson MedTech‘s Shockwave Medical today announced the full U.S. launch of its Shockwave E8 peripheral IVL catheter.
SamanTree Medical announced today that it received FDA 510(k) clearance for its Histolog scanner for tissue imaging.
SILVER SPRING, Md., Sept. 12, 2024 /PRNewswire/ — Today, the U.S. Food and Drug Administration authorized the first over-the-counter (OTC) hearing aid software device, Hearing Aid Feature, intended to be used with compatible versions of the Apple AirPods Pro headphones. Once installed and customized to the user’s hearing needs, the Hearing Aid Feature enables compatible versions of the AirPods Pro to serve as an OTC hearing aid, intended to amplify sounds for individuals 18 years or older with perceived mild to moderate hearing impairment.
AUSTIN, Texas, Sept. 12, 2024 /PRNewswire/ — NeuFit is revolutionizing neurological rehabilitation with its innovative approach that integrates advanced diagnostics and therapeutic technologies. At the center of NeuFit’s success is the NEUBIE (Neuro-Bio-Electric Stimulator), a cutting-edge device that utilizes direct current (DC) electrical stimulation to promote accelerated recovery, enhance performance, and improve overall well-being. This press release highlights NeuFit’s unique approach and its multi-site clinical trial collaboration with Hands-On Diagnostics (HODS) to address neuropathy.